Emgality® (Galcanezumab)

Para consultar la información para prescribir completa de Emgality® (Galcanezumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Galcanezumab: Mechanism of Action in Migraine Prevention

Galcanezumab is a humanized IgG4 mAb that binds CGRP and prevents its biological activity without blocking the CGRP receptor.

MX_cFAQ_GLC004_MOA_MIGRAINE
MX_cFAQ_GLC004_MOA_MIGRAINE
es-MX

The information contained in this letter may not completely match the current local labeling for GALCANEZUMAB. Please see local labeling approved in your country.

The Role of CGRP in Migraine

CGRP is

  • a 37-amino acid peptide commonly found in the peripheral and central nervous systems, and
  • considered a potent microvascular vasodilator.1-3

It has a potency approximately

  • 10 times higher than the most potent prostaglandins and
  • 10 to 100 times greater than acetylcholine and neuropeptide substance P.2

The CGRP neuropeptide has a wide range of physiological actions including cardiovascular regulatory processes and other conditions including but not limited to neurogenic inflammation, pain, and migraine. Migraine pathogenesis is thought to be associated with the activation of the trigeminovascular system. CGRP is distributed throughout the trigeminovascular system and is released from trigeminal ganglia nerves upon activation.2

The role of CGRP in migraine has been underscored by several experimental and clinical findings including,

  • an increase of jugular CGRP venous blood concentration during spontaneous migraine attacks
  • IV infusion of recombinant human CGRP triggered a migraine attack in migraine sufferers
  • elevated CGRP serum concentrations were inhibited by triptan treatment, and
  • small-molecule CGRP receptor antagonists were effective in relieving acute migraine headache in double-blind, randomized, placebo-controlled trials.4

The CGRP neuropeptide exists as α-CGRP and β-CGRP. The α-CGRP form is primarily associated with sensory neurons and is thought to have a major role in the pathogenesis of the migraine headache.2,3,5

The role of CGRP in migraine is further discussed in the following video and can be accessed at https://www.kaltura.com/tiny/u8dls.6

Mechanism of Action of Galcanezumab

Galcanezumab is a humanized IgG4 mAb that

  • binds CGRP, and
  • prevents its biological activity without blocking the CGRP receptor.7 

Galcanezumab targets CGRP and binds with high

  • affinity (Kd=31 pM), and
  • specificity (>10,000-fold versus related peptides adrenomedullin, amylin, calcitonin, and intermedin).7,8

When galcanezumab is administered, the premise is that

  • CGRP will bind to galcanezumab, and
  • the amount of free CGRP that is available to interact with the CGRP receptors will be reduced.7

Galcanezumab-bound CGRP is expected to take on the disposition characteristics of galcanezumab resulting in

  • a lower clearance than free CGRP, and
  • an increase in total CGRP concentration upon galcanezumab administration.7

In the phase 3 placebo-controlled, double-blind migraine prevention studies,9-11 total CGRP concentrations increased after galcanezumab administration in patients with episodic or chronic migraine compared to placebo. This indicated that the antibody was

  • binding to CGRP, and
  • slowing the clearance of the CGRP that was bound to the antibody.7,12

The binding of galcanezumab to CGRP is slowly reversible based on the off-rate for the CGRP/galcanezumab interaction determined experimentally. However, any released CGRP is likely to be quickly bound to the same or a different antibody based on the rapid on-rate for binding.1

Being a macromolecule, galcanezumab does not appreciably cross the blood-brain barrier. Therefore, it is thought that galcanezumab acts peripherally in structures involved in migraine pathogenesis, including the trigeminal ganglia.5,13,14

The mechanism of action of galcanezumab is further discussed in the following video and can be accessed at https://www.kaltura.com/tiny/mze6e.15

Referencias

1Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage. 2014;22(4):578-585. http://dx.doi.org/10.1016/j.joca.2014.01.009

2Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099-1142. http://dx.doi.org/10.1152/physrev.00034.2013

3Conner DL, Hay SG, Howitt K, et al. Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans. 2002;30(4):451-455. http://dx.doi.org/10.1042/bst0300451

4Dodick DW, Goadsby PJ, Spierings ELH, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885-892. http://dx.doi.org/10.1016/S1474-4422(14)70128-0

5Giamberardino MA, Affaitati G, Curto M, et al. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11(8):1045-1057. http://dx.doi.org/10.1007/s11739-016-1489-4

6CGRP and Migraine. Available at https://www.kaltura.com/tiny/u8dls. Accessed July 10, 2019.

7Data on file, Eli Lilly and Company and/or one of its subsidiaries.

8Monteith D, Collins EC, Vandermeulen C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740. http://dx.doi.org/10.3389/fphar.2017.00740

9Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

10Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

11Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

12Kielbasa W. Assessment of pharmacokinetics, target engagement and immunogenicity in patients with migraine administered galcanezumab, and anti-CGRP antibody. Poster presented at: 60th Annual Meeting of the American Headache Society (AHS): June 28 - July 1, 2018; San Francisco, CA.

13Nakano M, Uenaka K, Kielbasa W, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of LY2951742 (galcanezumab), a monoclonal antibody to calcitonin gene-related peptide, in healthy Japanese and Caucasian subjects. Poster presented at: the International Association of the Study of Pain (IASP)-World Congress on Pain Annual Meeting; September 26-30, 2016; Yokohama, Japan.

14Johnson K, Johnson MP, Ellis B, et al. Peripheral and central distribution of the CGRP neutralizing antibody [125I]-LY2951742 in male rats [abstract]. Headache. 2016;56(suppl 1):67:PS41. http://dx.doi.org/10.1111/head.12832

15Galcanezumab Binds to CGRP: Migraine. Available at https://www.kaltura.com/tiny/u8dls. Accessed July 10, 2019.

Glossary

CGRP = calcitonin gene-related peptide

IgG = immunoglobulin G

IgG4 = immunoglobulin G (subclass) 4

IV = intravenous

Kd = dissociation constant

mAb = monoclonal antibody

Fecha de la última revisión: 2019 M02 18


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta